Market Overview

Pacira Phase 3 Results For EXPAREL Demonstrated Statistical Significance For Both Primary And Secondary Endpoints In Upper Extremity Study But Did Not For The Lower Extremity Study, Timing For Resubmission Of Supplemental NDA Remains On Track

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: FDA

 

Related Articles (PCRX)

Partner Center